It is made available under a CC-BY-NC-ND 4.0 International license .

# 1 Adjusting for specificity of symptoms reveals higher prevalence of asymptomatic SARS-

- 2 CoV-2 infections than previously estimated
- 3
- Akshay Tiwari<sup>1</sup>, Shreya Chowdhury<sup>1</sup>, Ananthu James<sup>1,§</sup>, Budhaditya Chatterjee<sup>2,#</sup>, Narendra M.
   Dixit<sup>1,2,\*</sup>
- <sup>6</sup> <sup>1</sup>Department of Chemical Engineering, Indian Institute of Science, Bangalore, India 560012
- 7 <sup>2</sup>Department of Bioengineering, Indian Institute of Science, Bangalore, India 560012
- <sup>§</sup>Current address: Department of Public Health, Erasmus MC, University Medical Center
   Rotterdam, Rotterdam, The Netherlands
- 10 <sup>#</sup>Current address: Department of Microbiology and Immunology, School of Medicine, University
- 11 of Maryland Baltimore, Baltimore, MD, USA and NIAID, NIH, Bethesda, MD, USA
- 12 \*Correspondence: <u>narendra@iisc.ac.in</u>
- 13
- 14 Manuscript details:
- 15 Title: 127 characters; Abstract: 232 words; Text: ~2000 words; Figure: 1; References: 74
- 16 Supplementary Information: Table: 1; Figure: 1
- 17

It is made available under a CC-BY-NC-ND 4.0 International license .

# 18 ABSTRACT

19 Accurate estimates of the prevalence of asymptomatic SARS-CoV-2 infections,  $\psi$ , have been 20 important for understanding and forecasting the trajectory of the COVID-19 pandemic. Two-part population-based surveys, which test the infection status and also assess symptoms, have been 21 22 used to estimate  $\psi$ . Here, we identified a widely prevalent confounding effect that compromises 23 these estimates and devised a formalism to adjust for it. The symptoms associated with SARS-24 CoV-2 infection are not all specific to SARS-CoV-2. They can be triggered by a host of other 25 conditions, such as influenza virus infection. By not accounting for the source of the symptoms, 26 the surveys may misclassify individuals experiencing symptoms from other conditions as 27 symptomatic for SARS-CoV-2, thus underestimating  $\psi$ . We developed a rigorous formalism to 28 adjust for this confounding effect and derived a facile formula for the adjusted prevalence,  $\psi_{adi}$ . 29 We applied it to data from 50 published serosurveys, conducted on the general populations from 28 nations. We found that  $\psi_{adi}$  was significantly higher than the reported prevalence,  $\psi_c$ 30 31 (P=3×10<sup>-8</sup>). The median  $\psi_{adj}$  was ~60%, whereas the median  $\psi_c$  was ~40%. In several 32 instances,  $\psi_{adi}$  exceeded  $\psi_c$  by >100%. These findings suggest that asymptomatic infections have been far more prevalent than previously estimated. Our formalism can be readily deployed 33 34 to obtain more accurate estimates of  $\psi$  from standard population-based surveys, without 35 additional data collection. The findings have implications for understanding COVID-19 epidemiology and devising more effective interventions. 36

37

It is made available under a CC-BY-NC-ND 4.0 International license .

## 38 INTRODUCTION

39 Asymptomatic SARS-CoV-2 infections have been a major contributor to the spread of the 40 COVID-19 pandemic, with nearly a quarter of all transmission events attributed to them<sup>1</sup>. They also represent a key outcome of COVID-19 vaccination; vaccine efficacies have been estimated 41 42 as the fraction of potentially symptomatic infections rendered asymptomatic by vaccination in clinical trials<sup>2-4</sup>. Accurate estimation of the prevalence of asymptomatic infections,  $\psi$ , is thus 43 44 important for understanding COVID-19 epidemiology and for designing and assessing public 45 health interventions. A large number of surveys, conducted throughout the pandemic, have offered estimates of  $\psi^{5,6}$ . Here, we recognized an important confounding factor that 46 47 compromises these estimates and devised a formalism to adjust for it.

48 The surveys contain two parts: 1) a nucleic acid or an antibody test to detect SARS-CoV-2 49 infection, and 2) a questionnaire to assess the symptoms experienced. Individuals who test 50 positive for the infection but declare no symptoms are deemed asymptomatically infected.  $\psi$  is 51 thus estimated as the fraction of test-positive cases that reports no symptoms. The confounding 52 effect arises from the symptoms assessed not being specific to COVID-19. Symptoms such as cough and fever, which are part of nearly all COVID-19 surveys, can be triggered not only by 53 SARS-CoV-2 infection but also by a host of other infections including influenza and circulating 54 55 coronaviruses. It is possible, therefore, that some individuals who reported symptoms in the surveys may have had them due to the other conditions. Such individuals should be classified 56 57 as asymptomatic for SARS-CoV-2 but get misclassified as symptomatic, resulting in a systematic 58 underestimation of  $\psi$ .

59 Evidence of this misclassification exists in the data gathered by the surveys: The surveys identify 60 individuals who test negative for SARS-CoV-2 but report symptoms. For instance, a survey from The Netherlands reported that ~62% of the individuals who tested negative for SARS-CoV-2 61 62 displayed symptoms<sup>7</sup>. The number was as high as 80% in a survey in the US<sup>8,9</sup>. These individuals must have had their symptoms arise from causes other than SARS-CoV-2 infection. 63 The high prevalence of such individuals in these surveys implies that at least some of the test-64 positive, symptomatic cases may have had their symptoms arise from non-COVID conditions. 65 Adjusting for this confounding effect is important to obtain accurate estimates of  $\psi$ . 66

67 The adjustment is challenging because of the two-part survey methodology, with the tests used in the first part, to assess SARS-CoV-2 infection, limited by their own sensitivities and 68 69 specificities. Thus, the test-negative, symptomatic individuals, discussed above, may not all 70 have been uninfected; some who had the infection may have been classified as test-negative 71 because the antigen (or antibody) levels in them were below assay detection limits. Indeed, the 72 symptoms they experienced may well have arisen from SARS-CoV-2 infection. Thus, the 73 adjustment for the non-specificity of the symptoms must also simultaneously account for the 74 sensitivity and specificity of the SARS-CoV-2 test. Here, we developed a formalism that 75 accomplished that. We applied our formalism to data from 50 published serosurveys, conducted 76 in 28 countries across continents, and found that the adjusted  $\psi$  was significantly higher than 77 previously reported. Indeed, in several instances, the previous estimates had to be revised 78 upward by over 100%.

79

80 RESULTS

It is made available under a CC-BY-NC-ND 4.0 International license .

#### 81 Formalism to adjust for symptom specificity

82 We developed our formalism for the general scenario where the goal is to estimate the 83 prevalence of asymptomatic infections caused by a pathogen of interest when another pathogen that could trigger similar symptoms is also circulating in the population, confounding the 84 85 estimates. We assumed that data relating to the pathogen of interest was gathered following the 86 two-part survey methodology described above. The detailed derivation is presented in Methods. 87 Here, we let the pathogen of interest be SARS-CoV-2 and the other pathogen represent the 88 collection of all other conditions with symptoms that overlap with those of SARS-CoV-2 infection. 89 Remarkably, we obtained a closed-form expression for the adjusted prevalence of asymptomatic 90 SARS-CoV-2 infections,  $\psi_{adi}$ :

$$\psi_{adj} = 1 - \frac{\rho_c (1 - \rho_c)(\psi_c - 1 + \phi_c)(\alpha + \beta - 1)}{(\rho_c + \beta - 1)[\psi_c \rho_c (1 - \alpha) - \alpha(1 - \phi_c)(1 - \rho_c)]}$$
(1)

Here,  $\alpha$  and  $\beta$  are the SARS-CoV-2 test sensitivity and specificity, respectively,  $\psi_c$  is the crude (or unadjusted) prevalence of asymptomatic cases among test-positive individuals,  $\rho_c$  is the crude fraction of test-positive cases among the sampled individuals, and  $\phi_c$  is the crude proportion of symptomatic cases among test-negative individuals. Thus, given the set of quantities  $S = \{\alpha, \beta, \rho_c, \phi_c, \psi_c\}$ , all of which are typically reported in surveys,  $\psi_{adj}$  can be readily calculated.

#### 98 Adjusted estimates of $\psi$ from serosurveys

To apply our formalism, we collated data from published serosurveys (Table S1)<sup>7-56</sup>. Although our method applies also to surveys using nucleic acid-based (PCR) testing, serosurveys have been preferred for assessing asymptomatic SARS-CoV-2 infections because nucleic acid-based testing could miss presymptomatic individuals, who do not display symptoms at the time of testing but develop them later<sup>5,57</sup>. Serosurveys seek symptoms experienced during a longer 'recall period', which renders them more susceptible to confounding from other conditions with overlapping symptoms, highlighting the need for the present adjustment.

106 We considered serosurveys in the early phase of the pandemic, before vaccination programs 107 began, to eliminate any confounding effect of symptoms elicited by vaccines. We restricted our 108 analysis to studies with a sample size of  $\geq$  500, as smaller datasets could introduce significant uncertainties in our calculations<sup>58</sup>. We excluded studies on samples biased by symptom status, 109 110 such as hospitalized patients or long-term care facilities, and focused instead on studies 111 sampling the general population. We, of course, also excluded studies that did not provide all 112 the quantities in S required for the adjustment. With these criteria, we identified 50 serosurveys that were amenable to our analysis. Three of these studies<sup>13,39,56</sup> estimated  $\psi$  at three different 113 114 time points, resulting in a total of 56 estimates of  $\psi$  (Table S1). The selected studies spanned 28 115 countries across Asia, the Americas, Europe, and Africa, covering a broad spectrum of 116 epidemiological settings.

To first assess the prevalence and scale of the confounding effect due to the non-specificity of symptoms, we examined the fraction,  $\phi_c$ , of seronegative individuals who reported symptoms across the surveys.  $\phi_c$  varied from 0 to 0.8 with a median of 0.31 (Figure 1A), indicating that overlapping symptoms commonly arose from other conditions and could therefore significantly affect estimates of  $\psi$ . Furthermore, although most surveys employed antibody tests with high

It is made available under a CC-BY-NC-ND 4.0 International license .

122 sensitivity and specificity, several reported sensitivities ≤0.85 (Table S1), potentially amplifying

123 the confounding effect.

124





126 Figure 1. Adjusted estimates of the prevalence of asymptomatic SARS-CoV-2 infections are higher than crude estimates. Distributions of (A) fraction of test-negative individuals 127 showing symptoms,  $\phi_c$ , and **(B)** crude seroprevalence,  $\rho_c$ , from 50 serosurveys. **(C)** The 128 corresponding distributions of the reported crude prevalence of asymptomatic infections,  $\psi_c$ 129 (orange), and the adjusted prevalence,  $\psi_{adj}$  (red), the latter obtained using equation (1). The 130 dashed lines in (A)-(C) are medians. (D) Individual estimates of  $\psi_{adi}$  versus  $\psi_c$ . Error bars 131 indicate 95% confidence intervals calculated using the Wilson's score interval<sup>59</sup>. (E) Histogram 132 of the number of surveys with  $\eta$ , the percentage increase of  $\psi_{adi}$  over  $\psi_c$ , in the ranges shown. 133 The correlations between  $\eta$  and (F)  $\phi_c$ , and (G) test-specificity,  $\beta$ .  $r_s$  denotes Spearman's 134 135 correlation coefficient.

137 The crude seroprevalence,  $\rho_c$ , varied from 0.01 to 0.58 across the studies, with a median of 0.11, 138 representing a wide range of the extent of spread of the infection in the populations studied at 139 the time of the surveys (Figure 1B).

140 The surveys reported widely varying estimates of the crude prevalence of asymptomatic 141 infections,  $\psi_c$ , spanning the range from 0.068 to 1 with a median of 0.40 (Figure 1C, orange). Using equation (1), we calculated the adjusted prevalence,  $\psi_{adj}$ , for all the 56 estimates of  $\psi_c$ . 142  $\psi_{adj}$  varied from 0.04 to 1.00 with a median of 0.60 (Figure 1C, red). We found overall that  $\psi_{adj}$ 143 was significantly larger than  $\psi_c$  (P=3×10<sup>-8</sup> using the Wilcoxon signed rank test; Figure 1D). We 144 defined  $\eta = 100 \times (\psi_{adi} - \psi_c)/\psi_c$  as the percentage increase in  $\psi$  due to the adjustment. Out 145 146 of the 56 estimates, 9 had  $\eta$  >100%, 10 had  $\eta$  in the range of 50-100%, 12 in the range 25-50%, 147 21 between 0% and 25%, and 4 had  $\eta$ <0% (Figure 1E).

#### 148 Factors contributing to the adjustment

149 To identify the quantities in *S* most responsible for the adjustment in the datasets we considered,

150 we calculated pairwise correlations of  $\eta$  with each quantity in *S*. We found that  $\phi_c$  was strongly

positively correlated with  $\eta$  (Spearman's coefficient  $r_s = 0.86$ , P < 10<sup>-16</sup>) (Figure 1F).  $\beta$  showed a

moderate positive correlation with  $\eta$  ( $r_s = 0.30$ , P = 0.026) (Figure 1G). The other quantities were

not significantly correlated with  $\eta$  (Figure S1). Thus, the non-specificity of the symptoms was the major contributor to the adjustment. Indeed, for the 9 estimates with  $\eta$ >100%,  $\phi_c$  was >50%.

Our expression in equation (1) reduced when  $\alpha = \beta = 1$  to  $\psi_{adj} = \frac{\psi_c}{1-\phi_c}$ , showing how  $\phi_c$  would 155 contribute to the adjustment even with a perfect antibody test and explaining the positive 156 157 correlation between  $\psi_{adj}$  and  $\phi_c$ . For imperfect antibody tests, where  $\alpha < 1$  and/or  $\beta < 1$ ,  $\psi_{adj}$  displayed a more complex dependency on the quantities in *S* (equation (1)). In the absence 158 of symptom overlap ( $\phi_c = 0$ ), equation (1) reduced to  $\psi_{adj} = 1 - \frac{\rho_c(1-\rho_c)(\psi_c-1)(\alpha+\beta-1)}{(\rho_c+\beta-1)[\psi_c\rho_c(1-\alpha)-\alpha(1-\rho_c)]}$ 159 allowing  $\psi_{adi}$  to be larger or smaller than  $\psi_c$  depending on the specific values of  $\alpha$ ,  $\beta$ , and  $\rho_c$ . 160 When  $\alpha = 1$ , for instance,  $\psi_{adj} = 1 - (1 - \psi_c) \frac{\rho_c \beta}{\rho_c + \beta - 1} < \psi_c$ . (The latter inequality follows 161 because  $(1 - \beta)(1 - \rho_c) > 0$  and hence  $\frac{\rho_c \beta}{\rho_c + \beta - 1} > 1$ .) Indeed, the reduction in  $\psi$  due to imperfect 162 163 test sensitivity and specificity may dominate the increase due to overlapping symptoms, 164 explaining the few instances with  $\eta < 0\%$  above. Nonetheless, in all but 4 of the 56 instances we studied, we found  $\psi_{adj} \ge \psi_c$ , highlighting the dominant effect of the adjustment due to symptom 165 166 overlap.

167 We conclude therefore that  $\psi$  has been substantially underestimated by existing serosurveys, 168 primarily due to the confounding effect of the non-specificity of the symptoms elicited by SARS-169 CoV-2. Our formalism enables adjusting for this effect and arriving at more accurate estimates 170 of  $\psi$ .

171

#### 172 DISCUSSION

173 Our formalism makes important advances in addressing confounding effects in the estimation of

174  $\psi$ . A general formalism to adjust for antibody (or nucleic acid) test sensitivity and specificity was

developed earlier<sup>60</sup>, which has been applied to obtain accurate SARS-CoV-2 prevalence 175 176 estimates during the pandemic<sup>7</sup>. The formalism has been extended to estimate  $\psi$ , but without accounting for the specificity of the symptoms<sup>46</sup>. The importance of symptom specificity has been 177 178 recognized earlier: For instance, an increase in the proportion of asymptomatic cases of 179 influenza virus infection resulted after accounting for overlapping symptoms caused by other infections<sup>61,62</sup>. The adjustment in the latter studies, which relied on regression techniques, did 180 181 not account, however, for the infection test sensitivity and specificity. Here, we accounted for the 182 infection test sensitivity and specificity as well as the specificity of the symptoms. Furthermore, 183 we derived a closed-form expression for the adjustment (equation (1)) which enables facile 184 application of our formalism.

185 We foresee several implications of our study. First, the refined estimates of  $\psi$  that our formalism yields would help reassess the contribution of asymptomatic infections to COVID-19 186 transmission and spread<sup>1,63</sup>. They would also form inputs to models of COVID-19 187 188 epidemiology<sup>64-66</sup>, enabling more reliable forecasting of disease spread and the design of 189 effective control strategies. Second, the formalism could aid COVID-19 vaccine development 190 efforts<sup>67</sup> by enabling more accurate estimation of vaccine efficacies, which are often based on 191 comparing estimates of  $\psi$  in the vaccinated and unvaccinated arms of clinical trials<sup>2-4</sup>. Third, 192 estimates of  $\psi$  will inform efforts underway to unravel genetic, immunological, and demographic underpinnings of asymptomatic infections<sup>68-72</sup>. Finally, we anticipate our formalism to be 193 applicable to settings beyond COVID-19 that involve asymptomatic infections, such as 194 influenza<sup>61,62</sup>. It would be particularly important to epidemiological studies that employ extended 195 196 symptom recall periods, which increase the likelihood of contracting other infections during the 197 recall period and, consequently, the confounding effect of symptom overlap.

198 Our study has limitations. First, we assumed that symptoms caused by SARS-CoV-2 and by 199 other infections are independent. While co-infection can potentially influence the severity of 200 SARS-CoV-2 infection, such instances appear rare<sup>73</sup>. Further justification of our assumption 201 comes from studies that found influenza vaccination not to offer significant protection against SARS-CoV-2 symptoms<sup>74</sup>. Second, our selection of serosurveys is not exhaustive. Our aim was 202 203 to demonstrate the wide applicability and relevance of our formalism and not to provide a global 204 estimate of  $\psi$ . Future studies may conduct a more systematic search and meta-analysis using 205 our formalism to obtain such a global estimate of  $\psi$ .

206

#### 207 METHODS

#### 208 Formalism to adjust for specificity of symptoms

209 We consider the scenario where infection by the pathogen of interest, denoted X, can trigger 210 symptoms that may also be triggered by other pathogens (or conditions), the latter collectively 211 denoted Y. Surveys aim to assess the prevalence of asymptomatic infections by X. A test, de-212 noted T, assesses whether an individual undertaking the test is infected by X. Simultaneously, a 213 questionnaire inquires into the symptoms, denoted S, experienced by the individual during a pre-214 defined recall period. We recognize that the symptoms may also be triggered by Y. We distinguish between these possibilities by letting  $S_x$  and  $S_y$  represent events associated with the symp-215 216 toms being triggered by X and Y, respectively. The aim is to estimate the fraction of individuals

infected by *X* who do not experience symptoms triggered by *X*. We arrive at this estimate as follows.

We define  $P[X^+]$  and  $P[T^+]$  as the probability with which an individual is infected by X and the 219 probability that the infection test yields a positive result, respectively. Clearly,  $P[T^+] = \rho_c$ , the 220 221 crude prevalence estimated by the survey as the fraction of individuals tested who show a pos-222 itive result.  $P[X^+] = \rho_{adi}$  is the actual prevalence, obtained after adjusting for test sensitivity and specificity. The test sensitivity is  $\alpha = P[T^+|X^+]$ , the probability of the test yielding a positive result 223 given the infection by X. The test specificity is  $\beta = P[T^{-}|X^{-}]$ , the probability that the test yields 224 a negative result, given that the tested individual is not infected by X. The total probability of the 225 226 test yielding a positive result can thus be written as

227 
$$P[T^+] = P[T^+|X^+]P[X^+] + P[T^+|X^-]P[X^-]$$
(2)

Recognizing that  $P[T^+|X^+] = 1 - P[T^-|X^-]$  and  $P[X^-] = 1 - P[X^+]$  and substituting the definitions above in equation (2), it follows that

$$\rho_{adj} = \frac{\rho_c + \beta - 1}{\alpha + \beta - 1} \tag{3}$$

We next consider events related to the occurrence of symptoms. The crude prevalence of asymptomatic individuals,  $\psi_c = P[S^-|T^+]$ , is the probability that an individual who tests positive reports no symptoms. It is thus measured in the surveys as the fraction of test-positive cases who declare no symptoms. Accounting for the test sensitivity and specificity, we again write,

235 
$$P[S^{-}|T^{+}] = P[S^{-}|X^{+}]P[X^{+}|T^{+}] + P[S^{-}|X^{-}]P[X^{-}|T^{+}]$$
(4)

which, upon recognizing that  $P[X^-|T^+] = 1 - P[X^+|T^+]$  and invoking Bayes' theorem,

237 
$$P[X^+|T^+] = \frac{P[T^+|X^+]P[X^+]}{P[T^+]} = \frac{\alpha \rho_{adj}}{\rho_c}$$
(5)

238 yields

239

243

$$\psi_c = P[S^-|X^+] \frac{\alpha \rho_{adj}}{\rho_c} + P[S^-|X^-] \left(1 - \frac{\alpha \rho_{adj}}{\rho_c}\right)$$
(6)

Given the simultaneous presence of *X* and *Y* in circulation, the absence of symptoms implies the absence of symptoms triggered by both *X* and *Y*. In other words,  $\{S^-\} = \{S_X^-\} \cap \{S_Y^-\}$ . This yields,

$$P[S^{-}|X^{+}] = P[S_{X}^{-}|X^{+}]P[S_{Y}^{-}|X^{+}]$$
(7)

where  $P[S_X^-|X^+] = \psi_{adj}$  is the probability that an individual infected by *X* does not experience symptoms triggered by *X*, which is the adjusted prevalence of asymptomatic infections, the key quantity of interest here.

247 Similarly, in the absence of infection by *X*, we may write

248 
$$P[S^{-}|X^{-}] = P[S_{X}^{-}|X^{-}]P[S_{Y}^{-}|X^{-}] = P[S_{Y}^{-}|X^{-}]$$
(8)

where the latter equality follows from  $P[S_X^-|X^-] = 1$ ; an individual not infected by *X* cannot have symptoms triggered by *X*.

251 Combining equations (6) - (8) yields

$$\psi_c = \psi_{adj} P[S_Y^-|X^+] \frac{\alpha \rho_{adj}}{\rho_c} + P[S_Y^-|X^-] \left(1 - \frac{\alpha \rho_{adj}}{\rho_c}\right)$$
(9)

We next assume that experiencing symptoms triggered by Y or not is independent of infection by X, so that

252

$$P[S_{Y}^{-}|X^{+}] = P[S_{Y}^{-}|X^{-}]$$
(10)

To estimate the latter probabilities, we invoke their relationship with test results as follows. We recognize that  $\omega_c = P[S^-|T^-]$  is the probability of not experiencing symptoms given test-negative status, which represents the crude proportion of asymptomatic cases among test-negative individuals. Following the arguments above, the symptoms must arise neither from *X* nor *Y*, so that

260 
$$\omega_c = P[S^-|T^-] = P[S_X^-|T^-]P[S_Y^-|T^-]$$
(11)

261 Invoking test sensitivity and specificity, we write the first term on the right hand side of equation 262 (11) as

263 
$$P[S_X^-|T^-] = P[S_X^-|X^+]P[X^+|T^-] + P[S_X^-|X^-]P[X^-|T^-] \\ = \psi_{adj}P[X^+|T^-] + (1 - P[X^+|T^-])$$
(12)

where the latter equality follows because  $P[S_X^-|X^-] = 1$  and  $P[X^-|T^-] = 1 - P[X^+|T^-]$ . Using Bayes' theorem and the definitions of the quantities above, we obtain

266 
$$P[X^+|T^-] = \frac{P[T^-|X^+]P[X^+]}{P[T^-]} = \frac{(1-\alpha)\rho_{adj}}{1-\rho_c}$$
(13)

267 Combining equations (11) - (13) and rearranging terms yields

268 
$$P[S_X^-|T^-] = \psi_{adj} \frac{(1-\alpha)\rho_{adj}}{1-\rho_c} + \frac{1-\rho_c - \rho_{adj} + \alpha \rho_{adj}}{1-\rho_c}$$
(14)

Following a similar procedure, we write the second term on the right hand side of equation (11) as

271 
$$P[S_Y^-|T^-] = P[S_Y^-|X^+]P[X^+|T^-] + P[S_Y^-|X^-](P[X^-|T^-]) = P[S_Y^-|X^+]$$
(15)

where the latter equality follows because  $P[S_Y^-|X^+] = P[S_Y^-|X^-]$  and  $P[X^+|T^-] = 1 - P[X^-|T^-]$ . Combining equations (14) and (15) with equation (11) and rearranging terms, we obtain

274 
$$P[S_Y^-|X^+] = \frac{\omega_c(1-\rho_c)}{(\psi_{adj}-1)(1-\alpha)\rho_{adj}+1-\rho_c}$$
(16)

Finally, combining equations (9), (10), (11), and (16), and letting  $\phi_c = 1 - \omega_c$ , the fraction of

symptomatic cases in the test-negative subpopulation, we obtain equation (1):

It is made available under a CC-BY-NC-ND 4.0 International license .

277 
$$\psi_{adj} = 1 - \frac{\rho_c (1 - \rho_c)(\psi_c - 1 + \phi_c)(\alpha + \beta - 1)}{(\rho_c + \beta - 1)[\psi_c \rho_c (1 - \alpha) - \alpha(1 - \phi_c)(1 - \rho_c)]}$$

278

279

# 280 ACKNOWLEDGEMENTS

We thank Jeremie Guedj and Shreyas Joshi for helpful discussions. This study did not receive any funding.

283

## 284 AUTHOR CONTRIBUTIONS

A.T. and N.M.D. designed the study and developed the mathematical formalism. A.T. collated data from serosurveys, performed the analysis, and wrote the first draft. S.C., A.J., B.C. and N.M.D. contributed to the analysis and edited the draft. A.T. and S.C. had access to all the data. All authors approved the final draft and submission.

289

## 290 **COMPETING INTERESTS**

- 291 The authors declare that no competing interests exist.
- 292

# 293 **REFERENCES**

- 294 Johansson, M.A., Quandelacy, T.M., Kada, S., Prasad, P.V., Steele, M., Brooks, J.T., 1. 295 Slayton, R.B., Biggerstaff, M., and Butler, J.C. (2021). SARS-CoV-2 transmission from 296 people without COVID-19 JAMA Netw. e2035057. symptoms. Open 4. 297 10.1001/jamanetworkopen.2020.35057.
- Khoury, D.S., Cromer, D., Reynaldi, A., Schlub, T.E., Wheatley, A.K., Juno, J.A.,
   Subbarao, K., Kent, S.J., Triccas, J.A., and Davenport, M.P. (2021). Neutralizing antibody
   levels are highly predictive of immune protection from symptomatic SARS-CoV-2
   infection. Nat. Med. 27, 1205-1211. 10.1038/s41591-021-01377-8.
- Khoury, D.S., Docken, S.S., Subbarao, K., Kent, S.J., Davenport, M.P., and Cromer, D.
   (2023). Predicting the efficacy of variant-modified COVID-19 vaccine boosters. Nat. Med.
   29, 574-578. 10.1038/s41591-023-02228-4.
- Padmanabhan, P., Desikan, R., and Dixit, N.M. (2022). Modeling how antibody responses
  may determine the efficacy of COVID-19 vaccines. Nat. Comput. Sci. 2, 123-131.
  10.1038/s43588-022-00198-0.
- 3085.Oran, D.P., and Topol, E.J. (2021). The proportion of SARS-CoV-2 infections that are309asymptomatic : A systematic review. Ann. Intern. Med. *174*, 655-662. 10.7326/M20-6976.
- Sah, P., Fitzpatrick, M.C., Zimmer, C.F., Abdollahi, E., Juden-Kelly, L., Moghadas, S.M.,
   Singer, B.H., and Galvani, A.P. (2021). Asymptomatic SARS-CoV-2 infection: A
   systematic review and meta-analysis. Proc. Natl. Acad. Sci. USA *118*, e2109229118.
   doi:10.1073/pnas.2109229118.

- Vos, E.R.A., den Hartog, G., Schepp, R.M., Kaaijk, P., van Vliet, J., Helm, K., Smits, G.,
  Wijmenga-Monsuur, A., Verberk, J.D.M., van Boven, M., et al. (2020). Nationwide
  seroprevalence of SARS-CoV-2 and identification of risk factors in the general population
  of the Netherlands during the first epidemic wave. J Epidemiol. Community Health *75*,
  489-495. 10.1136/jech-2020-215678.
- Sullivan, P.S., Siegler, A.J., Shioda, K., Hall, E.W., Bradley, H., Sanchez, T., Luisi, N.,
   Valentine-Graves, M., Nelson, K.N., Fahimi, M., et al. (2022). Severe acute respiratory
   syndrome coronavirus 2 cumulative incidence, United States, August 2020-December
   2020. Clin. Infect. Dis. 74, 1141-1150. 10.1093/cid/ciab626.
- Chamberlain, A.T., Toomey, K.E., Bradley, H., Hall, E.W., Fahimi, M., Lopman, B.A., Luisi,
   N., Sanchez, T., Drenzek, C., Shioda, K., et al. (2022). Cumulative incidence of SARS CoV-2 infections among adults in Georgia, United States, August to December 2020. J.
   Infect. Dis. 225, 396-403. 10.1093/infdis/jiab522.
- Menezes, A.M.B., Victora, C.G., Hartwig, F.P., Silveira, M.F., Horta, B.L., Barros, A.J.D.,
  Mesenburg, M.A., Wehrmeister, F.C., Pellanda, L.C., Dellagostin, O.A., et al. (2021). High
  prevalence of symptoms among Brazilian subjects with antibodies against SARS-CoV-2.
  Sci Rep *11*, 13279. 10.1038/s41598-021-92775-y.
- Silva, A.A.M.D., Lima-Neto, L.G., Azevedo, C., Costa, L., Bragança, M., Barros Filho,
  A.K.D., Wittlin, B.B., Souza, B.F., Oliveira, B., Carvalho, C.A., et al. (2020). Populationbased seroprevalence of SARS-CoV-2 and the herd immunity threshold in Maranhao.
  Rev. Saude Publica *54*, 131. 10.11606/s1518-8787.2020054003278.
- Terças-Trettel, A.C.P., Muraro, A.P., Andrade, A.C.S., and Oliveira, E.C. (2022). Selfreported symptoms and seroprevalence against SARS-CoV-2 in the population of Mato
  Grosso: a household-based survey in 2020. Rev. Assoc. Med. Bras. (1992) 68, 928-934.
  10.1590/1806-9282.20220078.
- Albuquerque, J.O.M., Kamioka, G.A., Madalosso, G., Costa, S.A., Ferreira, P.B., Pino,
  F.A., Sato, A.P.S., Carvalho, A.C.A., Amorim, A.B.P., Aires, C.C., et al. (2021). Prevalence
  evolution of SARS-CoV-2 infection in the city of Sao Paulo, 2020-2021. Rev. Saude
  Publica *55*, 62. 10.11606/s1518-8787.2021055003970.
- Nwosu, K., Fokam, J., Wanda, F., Mama, L., Orel, E., Ray, N., Meke, J., Tassegning, A.,
  Takou, D., Mimbe, E., et al. (2021). SARS-CoV-2 antibody seroprevalence and associated
  risk factors in an urban district in Cameroon. Nat. Commun. *12*, 5851. 10.1038/s41467021-25946-0.
- Vial, P.A., González, C., Apablaza, M., Vial, C., Lavín, M.E., Araos, R., Rubilar, P., Icaza,
  G., Florea, A., Pérez, C., et al. (2022). First wave of SARS-CoV-2 in Santiago Chile:
  Seroprevalence, asymptomatic infection and infection fatality rate. Epidemics *40*, 100606.
  10.1016/j.epidem.2022.100606.
- 16. Vial, P., González, C., Icaza, G., Ramirez-Santana, M., Quezada-Gaete, R., NúñezFranz, L., Apablaza, M., Vial, C., Rubilar, P., Correa, J., et al. (2022). Seroprevalence,
  spatial distribution, and social determinants of SARS-CoV-2 in three urban centers of
  Chile. BMC Infect. Dis. 22, 99. 10.1186/s12879-022-07045-7.
- Li, Z., Guan, X., Mao, N., Luo, H., Qin, Y., He, N., Zhu, Z., Yu, J., Li, Y., Liu, J., et al.
  (2021). Antibody seroprevalence in the epicenter Wuhan, Hubei, and six selected
  provinces after containment of the first epidemic wave of COVID-19 in China. Lancet Reg.
  Health. West. Pac. *8*, 100094. 10.1016/j.lanwpc.2021.100094.

- 18. Garay, E., Serrano-Coll, H., Rivero, R., Gastelbondo, B., Faccini-Martínez, A., Berrocal,
  J., Pérez, A., Badillo, M., Martinez-Bravo, C., Botero, Y., et al. (2022). SARS-CoV-2 in
  eight municipalities of the Colombian tropics: high immunity, clinical and
  sociodemographic outcomes. Trans. R. Soc. Trop. Med. Hyg. *116*, 139-147.
  10.1093/trstmh/trab094.
- Serrano-Coll, H., Miller, H., Rodríguez-Van Der Hamen, C., Gastelbondo, B., Novoa, W.,
  Oviedo, M., Rivero, R., Garay, E., and Mattar, S. (2021). High prevalence of SARS-CoVin an Indigenous community of the Colombian Amazon region. Trop. Med. Infect. Dis.
  10.3390/tropicalmed6040191.
- State 20. Espenhain, L., Tribler, S., Svaerke Jørgensen, C., Holm Hansen, C., Wolff Sönksen, U.,
  and Ethelberg, S. (2021). Prevalence of SARS-CoV-2 antibodies in Denmark: Nationwide,
  population-based seroepidemiological study. Eur. J. Epidemiol. 36, 715-725.
  10.1007/s10654-021-00796-8.
- Shaweno, T., Abdulhamid, I., Bezabih, L., Teshome, D., Derese, B., Tafesse, H., and
  Shaweno, D. (2021). Seroprevalence of SARS-CoV-2 antibody among individuals aged
  above 15 years and residing in congregate settings in Dire Dawa city administration,
  Ethiopia. Trop. Med. Health *49*, 55. 10.1186/s41182-021-00347-7.
- Carrat, F., de Lamballerie, X., Rahib, D., Blanché, H., Lapidus, N., Artaud, F., Kab, S.,
  Renuy, A., Szabo de Edelenyi, F., Meyer, L., et al. (2021). Antibody status and cumulative
  incidence of SARS-CoV-2 infection among adults in three regions of France following the
  first lockdown and associated risk factors: a multicohort study. Int. J. Epidemiol. *50*, 14581472. 10.1093/ije/dyab110.
- 381 23. Rouquette, A., Descarpentry, A., Dione, F., Falissard, B., Legleye, S., Vuillermoz, C., 382 Pastorello, A., Meyer, L., Warszawski, J., Davisse-Paturet, C., et al. (2023). Comparison 383 of depression and anxiety following self-reported COVID-19-like symptoms vs SARS-384 CoV-2 seropositivity in France. JAMA Netw. Open 6, e2312892. 385 10.1001/jamanetworkopen.2023.12892.
- Beaumont, A., Durand, C., Ledrans, M., Schwoebel, V., Noel, H., Le Strat, Y., Diulius, D.,
  Colombain, L., Médus, M., Gueudet, P., et al. (2021). Seroprevalence of anti-SARS-CoVantibodies after the first wave of the COVID-19 pandemic in a vulnerable population in
  France: A cross-sectional study. BMJ Open *11*, e053201. 10.1136/bmjopen-2021-053201.
- Santos-Hövener, C., Neuhauser, H.K., Rosario, A.S., Busch, M., Schlaud, M., Hoffmann,
  R., Gößwald, A., Koschollek, C., Hoebel, J., Allen, J., et al. (2020). Serology- and PCRbased cumulative incidence of SARS-CoV-2 infection in adults in a successfully contained
  early hotspot (CoMoLo study), Germany, May to June 2020. Euro. Surveill. 25.
  10.2807/1560-7917.ES.2020.25.47.2001752.
- Weis, S., Scherag, A., Baier, M., Kiehntopf, M., Kamradt, T., Kolanos, S., Ankert, J.,
  Glöckner, S., Makarewicz, O., Hagel, S., et al. (2021). Antibody response using six
  different serological assays in a completely PCR-tested community after a coronavirus
  disease 2019 outbreak-the CoNAN study. Clin. Microbiol. Infect. 27, 470 e471-470 e479.
  10.1016/j.cmi.2020.11.009.
- 400 27. Merkely, B., Szabó, A.J., Kosztin, A., Berényi, E., Sebestyén, A., Lengyel, C., Merkely, G.,
  401 Karády, J., Várkonyi, I., Papp, C., et al. (2020). Novel coronavirus epidemic in the
  402 Hungarian population, a cross-sectional nationwide survey to support the exit policy in
  403 Hungary. Geroscience *42*, 1063-1074. 10.1007/s11357-020-00226-9.

- 404 28. Murhekar, M.V., Bhatnagar, T., Selvaraju, S., Saravanakumar, V., Thangaraj, J.W.V.,
  405 Shah, N., Kumar, M.S., Rade, K., Sabarinathan, R., Asthana, S., et al. (2021). SARS406 CoV-2 antibody seroprevalence in India, August-September, 2020: Findings from the
  407 second nationwide household serosurvey. Lancet Glob. Health *9*, e257-e266.
  408 10.1016/S2214-109X(20)30544-1.
- Selvaraju, S., Kumar, M.S., Thangaraj, J.W.V., Bhatnagar, T., Saravanakumar, V., Kumar,
  C.P.G., Sekar, K., Ilayaperumal, E., Sabarinathan, R., Jagadeesan, M., et al. (2021).
  Population-based serosurvey for severe acute respiratory syndrome coronavirus 2
  transmission, Chennai, India. Emerg. Infect. Dis. 27, 586-589. 10.3201/eid2702.203938.
- Kumar, D., Sidhu, M., Dogra, S., Kumar, B., Sahni, B., Yadav, A.K., Bala, K., Kumari, R.,
  Mahajan, R., Bavoria, S., et al. (2022). Seroprevalence of anti SARS-CoV-2 IgG
  antibodies among adults in Jammu district, India: A community-based study. Indian J.
  Med. Res. *155*, 171-177. 10.4103/ijmr.IJMR 4489 20.
- Khan, S.M.S., Qurieshi, M.A., Haq, I., Majid, S., Ahmad, J., Ayub, T., Bhat, A.A., Fazili,
  A.B., Ganai, A.M., Jan, Y., et al. (2021). Seroprevalence of SARS-CoV-2-specific IgG antibodies in Kashmir, India, 7 months after the first reported local COVID-19 case: results of a population-based seroprevalence survey from October to November 2020. BMJ Open *11*, e053791. 10.1136/bmjopen-2021-053791.
- 422 32. Poustchi, H., Darvishian, M., Mohammadi, Z., Shayanrad, A., Delavari, A.,
  423 Bahadorimonfared, A., Eslami, S., Javanmard, S.H., Shakiba, E., Somi, M.H., et al.
  424 (2021). SARS-CoV-2 antibody seroprevalence in the general population and high-risk
  425 occupational groups across 18 cities in Iran: a population-based cross-sectional study.
  426 Lancet Infect. Dis. *21*, 473-481. 10.1016/S1473-3099(20)30858-6.
- Heavey, L., Garvey, P., Colgan, A.M., Thornton, L., Connell, J., Roux, T., Hunt, M.,
  O'Callaghan, F., Culkin, F., Keogan, M., et al. (2021). The study to investigate COVID-19
  infection in people living in Ireland (SCOPI): A seroprevalence study, June to July 2020.
  Euro Surveill. 26, 2001741. doi:<u>https://doi.org/10.2807/1560-</u>
  <u>7917.ES.2021.26.48.2001741</u>.
- 432 34. Pagani, G., Giacomelli, A., Conti, F., Bernacchia, D., Rondanin, R., Prina, A., Scolari, V.,
  433 Rizzo, A., Beltrami, M., Caimi, C., et al. (2021). Prevalence of SARS-CoV-2 in an area of
  434 unrestricted viral circulation: Mass seroepidemiological screening in Castiglione d'Adda,
  435 Italy. PLoS One *16*, e0246513. 10.1371/journal.pone.0246513.
- 436 35. Stefanelli, P., Bella, A., Fedele, G., Pancheri, S., Leone, P., Vacca, P., Neri, A., Carannante, A., Fazio, C., Benedetti, E., et al. (2021). Prevalence of SARS-CoV-2 lgG 437 438 antibodies in an area of northeastern Italy with a high incidence of COVID-19 cases: a 439 Microbiol. Infect. population-based studv. Clin. 27. 633 e631-633 e637. 440 10.1016/j.cmi.2020.11.013.
- Abdul-Raheem, R., Moosa, S., Waheed, F., Aboobakuru, M., Ahmed, I.N., Rafeeg, F.N.,
  and Saeed, M. (2021). A sero-epidemiological study after two waves of the COVID-19
  epidemic. Asian Pac. J. Allergy Immunol. 10.12932/AP-040721-1177.
- Sagara, I., Woodford, J., Kone, M., Assadou, M.H., Katile, A., Attaher, O., Zeguime, A.,
  Doucoure, M., Higbee, E., Lane, J., et al. (2022). Rapidly increasing severe acute
  respiratory syndrome coronavirus 2 seroprevalence and limited clinical disease in 3
  Malian communities: A prospective cohort study. Clin. Infect. Dis. *74*, 1030-1038.
  10.1093/cid/ciab589.

- Basto-Abreu, A., Carnalla, M., Torres-Ibarra, L., Romero-Martínez, M., Martinez-Barnetche, J., Lopez-Martínez, I., Aparicio-Antonio, R., Shamah-Levy, T., Alpuche-Aranda, C., Rivera, J.A., et al. (2022). Nationally representative SARS-CoV-2 antibody prevalence estimates after the first epidemic wave in Mexico. Nat. Commun. *13*, 589. 10.1038/s41467-022-28232-9.
- Arnaldo, P., Mabunda, N., Young, P.W., Tran, T., Sitoe, N., Chelene, I., Nhanombe, A.,
  Ismael, N., Júnior, A., Cubula, B., et al. (2022). Prevalence of severe acute respiratory
  syndrome coronavirus 2 (SARS-CoV-2) antibodies in the Mozambican population: A
  cross-sectional serologic study in 3 cities, July-August 2020. Clin. Infect. Dis. *75*, S285S293. 10.1093/cid/ciac516.
- 459 40. Okpala, O.V., Dim, C.C., Ugwu, C.I., Onyemaechi, S., Uchebo, O., Chukwulobelu, U.,
  460 Emembolu, C., Okoye, B., Igboekwu, C., Okoye, U.B., et al. (2021). Population
  461 seroprevalence of SARS-CoV-2 antibodies in Anambra State, South-East, Nigeria. Int. J.
  462 Infect. Dis. *110*, 171-178. 10.1016/j.ijid.2021.07.040.
- 463 41. Nisar, M.I., Ansari, N., Khalid, F., Amin, M., Shahbaz, H., Hotwani, A., Rehman, N., Pugh,
  464 S., Mehmood, U., Rizvi, A., et al. (2021). Serial population-based serosurveys for COVID465 19 in two neighbourhoods of Karachi, Pakistan. Int. J. Infect. Dis. *106*, 176-182.
  466 10.1016/j.ijid.2021.03.040.
- 467 42. Huamaní, C., Velásquez, L., Montes, S., Mayanga-Herrera, A., and Bernabé-Ortiz, A.
  468 (2021). SARS-CoV-2 seroprevalence in a high-altitude setting in Peru: adult population469 based cross-sectional study. PeerJ 9, e12149. 10.7717/peerj.12149.
- 470 43. Díaz-Vélez, C., Failoc-Rojas, V.E., Valladares-Garrido, M.J., Colchado, J., Carrera471 Acosta, L., Becerra, M., Moreno Paico, D., and Ocampo-Salazar, E.T. (2021). SARS-CoV472 2 seroprevalence study in Lambayeque, Peru. June-July 2020. PeerJ 9, e11210.
  473 10.7717/peerj.11210.
- 474 44. Reyes-Vega, M.F., Soto-Cabezas, M.G., Cárdenas, F., Martel, K.S., Valle, A., Valverde,
  475 J., Vidal-Anzardo, M., Falcón, M.E., Munayco, C.V., and Peru COVID-19 Working Group
  476 (2021). SARS-CoV-2 prevalence associated to low socioeconomic status and
  477 overcrowding in an LMIC megacity: A population-based seroepidemiological survey in
  478 Lima, Peru. EClinicalMedicine *34*, 100801. 10.1016/j.eclinm.2021.100801.
- 479 45. Moyano, L.M., Toledo, A.K., Chirinos, J., Vilchez Barreto, P.M.Q., Cavalcanti, S., Gamboa,
  480 R., Ypanaque, J., Meza, M., Noriega, S., Herrera, V., et al. (2023). SARS-CoV-2
  481 seroprevalence on the north coast of Peru: A cross-sectional study after the first wave.
  482 PLoS Negl. Trop. Dis. *17*, e0010794. 10.1371/journal.pntd.0010794.
- 483 46. Canto e Castro, L., Pereira, A.H.G., Ribeiro, R., Alves, C., Veloso, L., Vicente, V., Alves,
  484 D., Domingues, I., Silva, C., Gomes, A., et al. (2021). Prevalence of SARS-CoV-2
  485 antibodies after first 6 months of COVID-19 pandemic, Portugal. Emerg. Infect. Dis. 27,
  486 2878. 10.3201/eid2711.210636.
- 487 47. Kislaya, I., Gonçalves, P., Barreto, M., Sousa, R., Garcia, A.C., Matos, R., Guiomar, R.,
  488 Rodrigues, A.P., and on Behalf of ISNCOVID-19 Group (2021). Seroprevalence of SARS489 CoV-2 Infection in Portugal in May-July 2020: Results of the First National Serological
  490 Survey (ISNCOVID-19). Acta Med. Port. *34*, 87-94. 10.20344/amp.15122.
- 48. Talla, C., Loucoubar, C., Roka, J.L., Barry, M.A., Ndiaye, S., Diarra, M., Thiam, M.S.,
  Faye, O., Dia, M., Diop, M., et al. (2022). Seroprevalence of anti-SARS-CoV-2 antibodies
  in Senegal: a national population-based cross-sectional survey, between October and
  November 2020. IJID Reg *3*, 117-125. 10.1016/j.ijregi.2022.02.007.

- 49. Karachaliou, M., Moncunill, G., Espinosa, A., Castano-Vinyals, G., Jiménez, A., Vidal, M.,
  496 Santano, R., Barrios, D., Puyol, L., Carreras, A., et al. (2021). Infection induced SARS497 CoV-2 seroprevalence and heterogeneity of antibody responses in a general population
  498 cohort study in Catalonia Spain. Sci. Rep. *11*, 21571. 10.1038/s41598-021-00807-4.
- 50. Pérez-Gómez, B., Pastor-Barriuso, R., Pérez-Olmeda, M., Hernán, M.A., Oteo-Iglesias,
  500 J., Fernández de Larrea, N., Fernández-García, A., Martín, M., Fernández-Navarro, P.,
  501 Cruz, I., et al. (2021). ENE-COVID nationwide serosurvey served to characterize
  502 asymptomatic infections and to develop a symptom-based risk score to predict COVID503 19. J. Clin. Epidemiol. *139*, 240-254. 10.1016/j.jclinepi.2021.06.005.
- 504 51. Richard, A., Wisniak, A., Perez-Saez, J., Garrison-Desany, H., Petrovic, D., Piumatti, G.,
  505 Baysson, H., Picazio, A., Pennacchio, F., De Ridder, D., et al. (2022). Seroprevalence of
  506 anti-SARS-CoV-2 IgG antibodies, risk factors for infection and associated symptoms in
  507 Geneva, Switzerland: a population-based study. Scand. J. Public Health *50*, 124-135.
  508 10.1177/14034948211048050.
- 509 52. Alsuwaidi, A.R., Al Hosani, F.I., Al Memari, S., Narchi, H., Abdel Wareth, L., Kamal, H., Al
  510 Ketbi, M., Al Baloushi, D., Elfateh, A., Khudair, A., et al. (2021). Seroprevalence of COVID511 19 infection in the Emirate of Abu Dhabi, United Arab Emirates: a population-based cross512 sectional study. Int. J. Epidemiol. *50*, 1077-1090. 10.1093/ije/dyab077.
- 53. Lamba, K., Bradley, H., Shioda, K., Sullivan, P.S., Luisi, N., Hall, E.W., Mehrotra, M.L.,
  Lim, E., Jain, S., Kamali, A., et al. (2021). SARS-CoV-2 cumulative incidence and period
  seroprevalence: Results from a statewide population-based serosurvey in California.
  Open Forum Infect. Dis. *8*, ofab379. 10.1093/ofid/ofab379.
- 54. Pathela, P., Crawley, A., Weiss, D., Maldin, B., Cornell, J., Purdin, J., Schumacher, P.K.,
  518 Marovich, S., Li, J., Daskalakis, D., and NYC Serosurvey Team (2021). Seroprevalence
  519 of severe acute respiratory syndrome coronavirus 2 following the largest initial epidemic
  520 wave in the United States: Findings from New York City, 13 May to 21 July 2020. J. Infect.
  521 Dis. 224, 196-206. 10.1093/infdis/jiab200.
- 522 55. Kumar, M.S., Thangaraj, J.W.V., Saravanakumar, V., Selvaraju, S., Kumar, C.P.G., 523 Sabarinathan, R., Jagadeesan, M., Hemalatha, M.S., Rani, D.S., Jeyakumar, A., et al. 524 (2021). Monitoring the trend of SARS-CoV-2 seroprevalence in Chennai, India, July and 525 October 2020. Trans. R. Soc. Trop. Med. Hyg. *115*, 1350-1352. 10.1093/trstmh/trab136.
- 526 56. Sharma, N., Sharma, P., Basu, S., Saxena, S., Chawla, R., Dushyant, K., Mundeja, N., 527 Marak, Z., Singh, S., Singh, G., and Rustagi, R. (2022). The seroprevalence of severe 528 acute respiratory syndrome coronavirus 2 in Delhi, India: a repeated population-based 529 seroepidemiological study. Trans. R. Soc. Trop. Med. Hyg. *116*, 242-251. 530 10.1093/trstmh/trab109.
- 531 57. Meyerowitz, E.A., Richterman, A., Bogoch, II, Low, N., and Cevik, M. (2021). Towards an 532 accurate and systematic characterisation of persistently asymptomatic infection with 533 SARS-CoV-2. Lancet Infect. Dis. *21*, e163-e169. 10.1016/S1473-3099(20)30837-9.
- 534 58. Ioannidis, J.P.A. (2021). Infection fatality rate of COVID-19 inferred from seroprevalence data. Bull. World Health Organ. *99*, 19-33F. 10.2471/BLT.20.265892.
- 53659.Wallis, S. (2013). Binomial confidence intervals and contingency tests: Mathematical537fundamentals and the evaluation of alternative methods. J. Quant. Linguistics 20, 178-538208. 10.1080/09296174.2013.799918.
- 539 60. Rogan, W.J., and Gladen, B. (1978). Estimating prevalence from the results of a screening test. Amer. J. Epidemiol. *107*, 71-76. 10.1093/oxfordjournals.aje.a112510.

- 541 61. Leung, N.H.L., Xu, C., Ip, D.K.M., and Cowling, B.J. (2015). Review article: The fraction
  542 of influenza virus infections that are asymptomatic: A Systematic review and meta543 analysis. Epidemiology 26, 862-872. 10.1097/ede.00000000000340.
- 544 62. Wang, T.E., Lin, C.Y., King, C.C., and Lee, W.C. (2010). Estimating pathogen-specific 545 asymptomatic ratios. Epidemiology *21*, 726-728. 10.1097/EDE.0b013e3181e94274.
- Buitrago-Garcia, D., Egli-Gany, D., Counotte, M.J., Hossmann, S., Imeri, H., Ipekci, A.M.,
  Salanti, G., and Low, N. (2020). Occurrence and transmission potential of asymptomatic
  and presymptomatic SARS-CoV-2 infections: A living systematic review and metaanalysis. PLoS Med. *17*, e1003346.
- 64. Bertozzi, A.L., Franco, E., Mohler, G., Short, M.B., and Sledge, D. (2020). The challenges
  of modeling and forecasting the spread of COVID-19. Proc. Natl. Acad. Sci. USA *117*,
  16732-16738. doi:10.1073/pnas.2006520117.
- Loo, S.L., Howerton, E., Contamin, L., Smith, C.P., Borchering, R.K., Mullany, L.C., Bents,
  S., Carcelen, E., Jung, S.-m., Bogich, T., et al. (2024). The US COVID-19 and Influenza
  Scenario Modeling Hubs: Delivering long-term projections to guide policy. Epidemics *46*,
  100738. <u>https://doi.org/10.1016/j.epidem.2023.100738</u>.
- 557 66. Kissler, S.M., Tedijanto, C., Goldstein, E., Grad, Y.H., and Lipsitch, M. (2020). Projecting 558 the transmission dynamics of SARS-CoV-2 through the postpandemic period. Science 559 368, 860-868. doi:10.1126/science.abb5793.
- 560 67. Zhu, C., Pang, S., Liu, J., and Duan, Q. (2024). Current progress, challenges and 561 prospects in the development of COVID-19 vaccines. Drugs *84*, 403-423. 562 10.1007/s40265-024-02013-8.
- Augusto, D.G., Murdolo, L.D., Chatzileontiadou, D.S., Sabatino Jr, J.J., Yusufali, T.,
  Peyser, N.D., Butcher, X., Kizer, K., Guthrie, K., and Murray, V.W. (2023). A common allele
  of HLA is associated with asymptomatic SARS-CoV-2 infection. Nature 620, 128–136.
  <u>https://doi.org/10.1038/s41586-023-06331-x</u>.
- Marchal, A., Cirulli, E.T., Neveux, I., Bellos, E., Thwaites, R.S., Barrett, K.M.S., Zhang, Y.,
  Nemes-Bokun, I., Kalinova, M., and Catchpole, A. (2024). Lack of association between
  classical HLA genes and asymptomatic SARS-CoV-2 infection. HGG Adv. *5*, 100300.
  10.1016/j.xhgg.2024.100300.
- 571 70. Chowdhury, S., Tiwari, A., James, A., Chatterjee, B., and Dixit, N.M. (2023). Asymptomatic
  572 SARS-CoV-2 infections tend to occur less frequently in developed nations. medRxiv,
  573 2023.2012.2014.23299954. 10.1101/2023.12.14.23299954.
- 574 71. Owens, K., Esmaeili, S., and Schiffer, J.T. (2024). Heterogeneous SARS-CoV-2 kinetics 575 due to variable timing and intensity of immune responses. JCI Insight *9*, e176286. 576 10.1172/jci.insight.176286.
- 577 72. Chatterjee, B., Singh Sandhu, H., and Dixit, N.M. (2022). Modeling recapitulates the 578 heterogeneous outcomes of SARS-CoV-2 infection and quantifies the differences in the 579 innate immune and CD8 T-cell responses between patients experiencing mild and severe 580 symptoms. PLoS Pathog. *18*, e1010630.
- Pawlowski, C., Silvert, E., O'Horo, J.C., Lenehan, P.J., Challener, D., Gnass, E., 73. 581 582 Murugadoss, K., Ross, J., Speicher, L., Geyer, H., et al. (2022). SARS-CoV-2 and 583 influenza coinfection throughout the COVID-19 pandemic: an assessment of coinfection cohort characteristics. and clinical outcomes. PNAS Nexus 584 rates. 1. 585 10.1093/pnasnexus/pgac071.

It is made available under a CC-BY-NC-ND 4.0 International license .

- Almadhoon, H.W., Hamdallah, A., Elsayed, S.M., Hagrass, A.I., Hasan, M.T., Fayoud,
  A.M., Al-Kafarna, M., Elbahnasawy, M., Alqatati, F., Ragab, K.M., et al. (2022). The effect
  of influenza vaccine in reducing the severity of clinical outcomes in patients with COVID19: a systematic review and meta-analysis. Sci. Rep. *12*, 14266. 10.1038/s41598-02218618-6.
- 591